Fred Aslan

Fred Aslan, M.D., has a twenty-year track record as an executive and investor in the life sciences industry. He was most recently President and CBO at Vividion Therapeutics where he was responsible for business development, finance, alliance and project management, and operations. Fred had the opportunity to orchestrate Vividion’s Series B financing and $135M-upfront collaboration with Roche. Prior to Vividion, Fred had a 12 year affiliation with Venrock. Initially he was an investor from 2006 to 2013, when he co-founded and served as a board member of Receptos Pharmaceuticals (acquired by Celgene for more than $7 billion). Fred led Venrock’s investment in Zeltiq (acquired by Allergan for more than $2 billion), and was involved in the early formation of Fate Therapeutics. Subsequently as an entrepreneur from 2013 to 2018, he was CEO of Adavium Medical, a Brazilian medical device company, which he grew from zero to 350 employees, sales of over US$40 million, and fully integrated R&D, manufacturing and commercial capabilities. Prior to Venrock, Fred was Director of Business Development and Head of Investor Relations for CuraGen, a NASDAQ-listed oncology-focused biotech company. Prior to CuraGen, he was a consultant at Boston Consulting Group (BCG). Fred holds a BS in Biology from Duke University, an MD from Yale School of Medicine, and an MBA from Harvard Business School.